Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
Ricoh USA, Inc.
Var2 Pharmaceuticals
IGM Biosciences, Inc.
TopAlliance Biosciences
EpicentRx, Inc.
Tracon Pharmaceuticals Inc.
Emerald Clinical Inc.
Genentech, Inc.
Celgene
AEterna Zentaris
Novartis
Celldex Therapeutics
Valerio Therapeutics
Valerio Therapeutics
INSYS Therapeutics Inc
Infinity Pharmaceuticals, Inc.